Global Drugs for Vulvovaginal Candidiasis Market is segmented By Formulation Type (Topical, Pessary, Oral), By Drug Type (Miconazole, Clotrimazole, Fluconazole, Econazole), By End User (Hospital & Clinics, Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Drugs for Vulvovaginal Candidiasis Market Overview
The Global Drugs for Vulvovaginal Candidiasis Market is expected to grow at a CAGR of 3.2% during the forecasting period (2024-2031).
Candidiasis is an infection caused by a yeast called Candida fungi, among which the most common is Candida albicans. These fungi typically live on the skin and inside the body, in places such as the throat, gut, mouth, and vagina, without causing any problems. Candida fungi can cause infections, in case if it grows out of control or if it enters into the body, such as the bloodstream or internal organs, including the kidney, brain, or heart. However, candida infections are hardly ever serious in healthy people. It may even spread through other parts of the body if the patient's immune system is not working properly in fewer cases.
Drugs for Vulvovaginal Candidiasis Market Summary
|
Metrics |
Details |
|
Market CAGR |
3.2% |
|
Segments Covered |
By Formulation Type, By Drug Type, By End User and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Drugs for Vulvovaginal Candidiasis Market Dynamics
Certain factors leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.
The expected increase in the prevalence of candidiasis
Candidemia is one of the common bloodstream infections in the US. The average incidence was around 9 per 100,000 people, as per the Centers for Disease Control and Prevention (CDC). The organization has further estimated that approximately 25,000 cases of candidemia occur in the US each year. However, as per CDC, the incidence of candidemia declined among infants and older people in the US from 2009 to 2012. This decline was due to prophylaxis guidelines and enhanced infection control practices, such as catheter care and hand hygiene. Though, the incidence of candidemia is expected to increase during the forecast period, backed by the rise in the awareness of symptoms associated with candidemia slightly.
Increasing R&D expenditure and expansion of product pipeline
The market for fungal disease treatment has led to the introduction of several effective and safe antifungal agents. A few of the most effective therapies available in the market include itraconazole, terbinafine, and fluconazole. The increasing R&D spending by the pharmaceutical companies for the development of an advanced product pipeline for anti-infective drugs is one of the major factors augmenting the growth of the antifungal drug industry, which in turn, is expected to escalate the drugs for vulvovaginal candidiasis market. The market players focus on developing effective therapeutic agents in immunocompromised patients to cure systemic fungal infections, including candidemia.
COVID-19 Impact Analysis
An increase in the market value of drugs for vulvovaginal candidiasis is expected in 2020, backed by the rise in the prevalence of invasive candidiasis in patients dealing with COVID-19. This is due to the rise in healthcare-associated infections (HIAs), including bloodstream infections such as candidiasis, especially in patients admitted to hospitals. Therefore, the demand for drugs for vulvovaginal candidiasis increased amid the COVID-19 pandemic, which increased the sales of the drug in 2020.
Drugs for Vulvovaginal Candidiasis Market Segment Analysis
Based on the drug type, the drugs for the vulvovaginal candidiasis market have been classified into miconazole, clotrimazole, fluconazole, and econazole.
Miconazole segment contributed a significant share to the global drugs for vulvovaginal candidiasis market in 2019
Miconazole is a synthetic imidazole antifungal drug that eases the symptoms of candidiasis by killing the candida fungus. It is majorly used as an effective treatment for vaginal thrush and fungal infections in other parts of the body. It is an oral gel available in the market on a prescription from a doctor; however, it can also be bought in smaller packs from pharmacies without a prescription. It acts rapidly in relieving yeasts' symptoms, dermatophytes, and gram-positive bacteria, available for topical therapy of skin infections.
Based on the formulation type, the vulvovaginal candidiasis market drugs have been classified into topical, necessary, and oral.
Topical lead the market throughout the forecast period
The topical segment led the overall market with a share in 2019. A topical formulation of drugs for vulvovaginal candidiasis is used to treat diseases related to the vaginal yeast, which reduces vaginal itching, pain, and discharge with this condition. The topical drug is an antifungal azole, which functions by preventing the growth of the infection-causing yeast.
Drugs for Vulvovaginal Candidiasis Market Geographical Share
Based on geography, the study analyzes the drugs for the vulvovaginal candidiasis market globally, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.
North America leads the global market throughout the forecast period.
North America dominated the global drugs for vulvovaginal candidiasis market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American drugs for the vulvovaginal candidiasis market in 2019. The high awareness regarding the vaginal infection from candida is one of the major factors propelling the market's growth in the region. Moreover, the key market players are headquartered in the US, such as Pfizer Inc. and Johnson & Johnson Services Inc., are further escalating the growth of the market in North America.
Moreover, Asia Pacific is expected to project the fastest growth rate in the drugs for the vulvovaginal candidiasis market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia pacific drugs for vulvovaginal candidiasis market during the forecast period. The expansion of global market players in the Asia-Pacific region due to the rising prevalence of vulvovaginal candidiasis in the area are certain factors that will propel the market growth during the forecast period.
Drugs for Vulvovaginal Candidiasis Market Companies and Competitive Landscape
The drugs for the vulvovaginal candidiasis market are highly competitive, owing to the large presence of drugs for the vulvovaginal candidiasis brands. The key drugs for vulvovaginal candidiasis players include Actavis PLC, Bristol-Myers Squibb, Bayer AG, Effik SA, Cisen Pharmaceutical, Sanofi SA, Kingyork Group, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Services Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the drugs for the vulvovaginal candidiasis market.
Pfizer Inc.
Overview: Pfizer Inc. is a research-based pharmaceutical company engaged in the discovery, development, and marketing of healthcare products, including vaccines and medicines. The company operates its business across two segments: Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). The company develops and provides over 170 different vaccines and medicines to the global market.
Product Portfolio: The company's portfolio comprises fluconazole.
